Pfizer: Aspergillosis trials

The registry lists 11 Aspergillosis studies with Pfizer as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 2 3Phase 3 5Phase 4 3No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To Less Than 15 Years Old Who Are At High Risk For Systemic Fungal InfectionCompletedNCT01383993Phase 2Results posted
• Voriconazole (Vfend) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)CompletedNCT01151085Results posted
• A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy SubjectsCompletedNCT00940017Phase 4Results posted
• A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In ChildrenTerminatedNCT00836875Phase 3Results posted
• Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)TerminatedNCT00620074Phase 4Results posted
• Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive AspergillosisCompletedNCT00531479Phase 3Results posted
• Voriconazole For Chronic Bronchopulmonary AspergillosisCompletedNCT00159822Phase 2/3Results posted
• Post Marketing Surveillance (PMS) Study of Cresemba in Korea.CompletedNCT04744454
• Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric SubjectsWithdrawnNCT01188759Phase 3
• A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal InfectionsCompletedNCT00647907Phase 4
• A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).CompletedNCT00037206Phase 2/3